Posted by Michael Wonder on 16 Dec 2025
ICER publishes final evidence report on treatments for obesity
16 December 2025 - Independent committee voted unanimously on the positive net health benefit of all three treatments; final report includes key policy recommendations.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of semaglutide (injectable Wegovy, and a yet to be approved oral formulation) (Novo Nordisk) and tirzepatide (Zepbound) (Eli Lilly and Company) for the treatment of obesity. The final report includes key policy recommendations to help ensure fair access.
